Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is well-positioned for growth, with a diverse portfolio of drugs targeting key healthcare areas such as neuroscience, cardiometabolic, cancer, and immunology. The positive projected revenue and EPS, along with the company's CEO's goal for double-digit growth and expansion into new markets, further solidify its strong potential for success. Despite potential risks and competition, Eli Lilly's strong emphasis on innovation and acquisition strategy make it a promising stock for the future.

Bears say

Eli Lilly is experiencing a decline in their EP business, leading to a decrease in sales and earnings. Although they have multiple growth catalysts and a strong position in the MedTech industry, their stock performance is dependent on upcoming trial results and investor sentiment. There are also risks to the company's rating and price target, including potential competition, failed R&D efforts, and external factors such as supply chain disruptions and geopolitical issues. Overall, the negative outlook stems from the current decline in EP revenue and uncertainties surrounding future performance and external risks.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,223.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,223.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.